title: [Multivariate analysis of imatinib resistance-related factors during the treatment of chronic myeloid leukemia].
abstract: OBJECTIVE
  To explore efficacy of imatinib for patients with chronic myeloid leukemia(CML) and its resistance-related factors during the treatment.
  
  
  METHODS
  The clinical data of 214 CML patients received imatinib were analyzed respectively in our hospital from April 2005 to December 2010. The therapy history and efficacy of regular follow-up and factors influencing drug resistance were analyzed. COX regression analysis was used to perform the univariate and multivariate analysis.
  
  
  RESULTS
  Until the end of follow up, thirty-one patients (14.5%) occurred drug resistance. One of them was in accelerated phase(AP), and two in blast phase(BP); 69.2% of patients achieved a complete cytogenetic response(CCyR), and 31.3% of patients achieved a major molecular response(MMR). COX analysis was performed in 207 chronic phase(CP) patients. Univariate analysis showed that the course of disease before treatment, the hemoglobin count, the white blood cell count, whether achieved CCyR or not and whether achieved MMR or not were the influencing factors for imatinib resistance. Multivariate analysis showed that whether achieved CCyR or not was the independent factor for drug resistance.
  
  
  CONCLUSIONS
  Whether achieved CCyR or not is an independent factor and also a protective factor for imatinib resistance in patients with CML.
authors.affiliation: First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, Key Laboratory of Thrombosis and Hemostasis, Ministry of Health, Soochow 215006, China.
authors.forename: Min
authors.initials: M
authors.lastname: Zhou
authors.forename: Hui-ying
authors.initials: HY
authors.lastname: Qiu
authors.forename: Guang-sheng
authors.initials: GS
authors.lastname: He
authors.forename: Yang
authors.initials: Y
authors.lastname: Xu
authors.forename: Jian-nong
authors.initials: JN
authors.lastname: Cen
authors.forename: Jin-lan
authors.initials: JL
authors.lastname: Pan
authors.forename: Su-ning
authors.initials: SN
authors.lastname: Chen
authors.forename: Ai-ning
authors.initials: AN
authors.lastname: Sun
authors.forename: Ri
authors.initials: R
authors.lastname: Zhang
authors.forename: De-pei
authors.initials: DP
authors.lastname: Wu
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D001549:Benzamides / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D019008:Drug Resistance, Neoplasm; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D000068877:Imatinib Mesylate; D015466:Leukemia, Myeloid, Chronic-Phase / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D012189:Retrospective Studies; D055815:Young Adult
chemical_list: D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate